A5101982950- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Platelet Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Blood groups and transfusion
- Vascular Malformations and Hemangiomas
- Psychosomatic Disorders and Their Treatments
- COVID-19 epidemiological studies
- Infection Control and Ventilation
- Tumors and Oncological Cases
- Sarcoma Diagnosis and Treatment
- Blood disorders and treatments
- COVID-19 and Mental Health
- Neutropenia and Cancer Infections
- Acute Myeloid Leukemia Research
- Vascular Malformations Diagnosis and Treatment
- Virus-based gene therapy research
- Nutrition and Health in Aging
- Methemoglobinemia and Tumor Lysis Syndrome
- Lung Cancer Diagnosis and Treatment
- Syphilis Diagnosis and Treatment
- Hemophilia Treatment and Research
- Porphyrin Metabolism and Disorders
- Cardiac Valve Diseases and Treatments
- Urban Agriculture and Sustainability
Johns Hopkins All Children's Hospital
2018-2025
Johns Hopkins University
2018-2025
Centre d'Étude et de Recherche Travail Organisation Pouvoir
2023
Vince Lombardi Cancer Clinic
2021
University of Saint Mary of the Lake
2020
Johns Hopkins Medicine
2018
Mount Sinai Health System
2016
Sarasota Memorial Hospital
2013
University of South Florida
2005-2008
University of Regensburg
2008
Children with cancer frequently have associated cachexia and malnutrition. Failure to thrive affects nearly 40% of oncology patients advanced or progressive disease. Malnutrition can erode quality life adversely impact disease prognosis. Appetite stimulation increased food intake is 1 approach combat cancer-related cachexia.
Asparaginase is a standard treatment for acute lymphoblastic leukemia (ALL) of childhood. As bacteria-derived enzyme, asparaginase highly immunogenic, and hypersensitivity reactions (HSRs) routinely lead to drug discontinuation. HSRs remain common even with the introduction pegaspargase, PEGylated version Escherichia coli-derived asparaginase. Erwinia chrysanthemi (recombinant)-rywn (recombinant Erwinia) an alternative those pegaspargase. Here, we describe 11-year-old boy relapsed ALL who...
Abstract Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma (LL). To determine comorbidities present within 3 months before diagnosis ALL/LL patients, and to examine if varies by age, biological sex at birth, race/ethnicity. We analyzed data ≤21 years age from 1/1/2005 6/30/2020 (n=5,455), using electronic health records TriNetX Research Network Database. Comorbidities examined included pulmonary,...
<p>Prevalence of comorbidity by race/ethnicity among pediatric patients with ALL/LL. “Others” includes mostly African Americans, Hispanics, and Asians. Error bars indicate 95% CI.</p>
<div>Abstract<p>Limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma (LL). To determine comorbidities present within 3 months before diagnosis ALL/LL and to examine if varies by age, biological sex at birth, race/ethnicity, we analyzed data ≤21 years age from January 1, 2005, June 30, 2020 (<i>n</i> = 5,455), using electronic health records TriNetX Research Network database....
<p>Top 10 common diagnosis in genitourinary diseases (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
<p>Prevalence of comorbidity by biological sex at birth among pediatric patients with ALL/LL. Proportion female and male ALL/LL comorbidities. Error bars indicate 95% CI. F, female; M, male.</p>
<p>Characteristics of the patient cohort</p>
<p>Prevalence of comorbidity groups among pediatric patients with ALL/LL. Proportion ALL/LL different comorbidities. Error bars indicate 95% CI.</p>
<p>Top 10 common diagnosis in digestive tract disorders (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
<p>Prevalence of overall comorbidity by sex, age at diagnosis, and race/ethnicity</p>
<p>Prevalence of comorbidity by age at diagnosis among pediatric patients with ALL/LL. Proportion ALL/LL comorbidities diagnosed a younger (≤10 years) or older (>10 years). Error bars indicate 95% CI.</p>
<p>Top 10 common diagnosis in digestive tract disorders (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
<p>Top 10 common diagnosis in genitourinary diseases (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
Abstract Introduction: Comorbidities affect treatment outcomes in adult cancer. However, limited knowledge exists on the prevalence of comorbidity among pediatric patients diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma (LL). The aim this study was to determine comorbidities at diagnosis ALL/LL patients, and examine if varied by age, biological sex birth, race/ethnicity. Methods: We analyzed data ≤21 years age from 1/1/2005 6/30/2020 (n=5, 455), using TriNetX Research Network...
<p>Top 10 common diagnosis in genitourinary diseases (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
<p>Top 10 common diagnosis in digestive tract disorders (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>
<p>Top 10 common diagnosis in digestive tract disorders (with each code counted once per patient within the 3 months prior to their ALL/LL diagnosis, regardless of multiple occurrences)</p>